Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation develops and markets advanced therapies for sports medicine and severe burn care, with U.S. commercial products that include MACI, Epicel and NexoBrid. News about VCEL commonly covers financial results, MACI procedure and surgeon activity, burn care revenue trends, and manufacturing capacity for cell therapy products.
Company updates also include regulatory and operational milestones, such as FDA approval of commercial MACI manufacturing at Vericel's advanced therapy facility, as well as BARDA-supported procurement and development activities for NexoBrid. The recurring themes center on commercialization, specialty biologics supply, product access and development within Vericel's cellular therapy portfolio.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Vericel Corporation (NASDAQ:VCEL) is scheduled to report its first-quarter 2023 financial results on May 10, 2023. The company specializes in advanced therapies for sports medicine and serious burn care, offering products such as MACI® and Epicel®. A conference call will take place at 8:30 a.m. (ET) to discuss the results and key business highlights, accessible through the Investor Relations section of its website. Interested participants should register in advance to obtain dial-in details. A replay will be available until May 10, 2024.
Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present at the Canaccord Genuity Musculoskeletal Conference on March 7, 2023, at 12:30 p.m. ET. A webcast of this presentation can be accessed through Vericel's Investor Relations website. The company specializes in advanced therapies for sports medicine and severe burn care, offering products like MACI®, an autologous scaffold for knee cartilage defects, and Epicel®, a permanent skin replacement for severe burns. Vericel also holds exclusive rights to NexoBrid® for burn treatment. For further details, visit the company's official website.
Vericel Corporation (NASDAQ:VCEL) reported robust financial results for Q4 and full-year 2022, with total revenue reaching $52.7 million in Q4, a 31% increase in net income, and total annual revenue of $164.4 million. MACI revenue contributed $132 million for 2022, showing a 24% year-over-year growth in Q4. The company anticipates 2023 total revenue between $180 million and $188 million with MACI revenue estimated at $152 million to $156 million. Notably, Vericel achieved FDA approval for NexoBrid, paving the way for further growth.
Vericel Corporation (NASDAQ: VCEL) is set to report its fourth-quarter 2022 financial results on February 23, 2023. Management will host a conference call and webcast at 8:30 a.m. (ET) to discuss these results along with important business highlights. Interested participants can access the live webcast on Vericel's Investor Relations page and register for the call via the provided link to receive dial-in details. A replay will be available on their website until February 23, 2024. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing notable products like MACI® and Epicel®.